- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01390324
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine (Atenéia)
October 18, 2016 updated by: Ache Laboratorios Farmaceuticos S.A.
A Multicenter, National, Double-blind, Randomized Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Naratriptan 2,5 mg + Naproxen 500 mg Relative to Efficacy and Safety of Each Monotherapy for the Acute Treatment of Migraine
The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patient, age in the range of 18-65 years inclusive that has onset of migraine before age 50;
- Patient has at least a 3-month history of migraine with or without aura according to the ICHD-II, 2004, IHS (International Headache Society) criteria;
- Patients experienced an average migraine headache frequency of 2-6 moderate or severe attacks per month in the last 03 months prior to screening visit;
- Patients able to distinguish his/her migraine attacks from any other types of headaches;
- Patients able to understand and consent to participate in this clinical study, expressed by signing the Informed Consent (IC).
Exclusion Criteria:
- History of more than 6 migraine attacks/month in the last 03 months prior to screening visit;
- History of non-migraine headache frequency ≥ 15 days/month in each of the 3 months prior to screening.
- History of following migraine variants, according to the ICHD-II, 2004, IHS (International Headache Society): basilar migraine, aura without headache, familial hemiplegic migraine, sporadic hemiplegic migraine or aura with non-migraine headache;
- If female of childbearing potential, has a negative urine pregnancy test at Visit 0 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as determined by the investigator;
- Woman in pregnancy or lactation period;
- History of epilepsy or psychiatric condition that may affect the compliance of the treatment;
- Patients in acupuncture treatment for the symptoms of migraine attacks;
- Suffers from cardiovascular disease (ischemic heart disease, including angina pectoris, myocardial infarction, documented silent ischemia, or with Prinzmetal's angina) or has symptoms of ischemic heart disease;
- History of cerebrovascular pathology including stroke and/or transient ischemic attacks;
- History of allergic reactions to naproxen preparations, including subjects in whom aspirin or other NSAID drugs induce the syndrome of asthma, rhinitis, nasal polyps or urticaria;
- Diagnosis of renal or hepatic failure;
- Has significant (as determined by the investigator) cardiovascular risk factors that may include uncontrolled high blood pressure, post-menopausal women, males over 40 years old, hypercholesterolemia, obesity, diabetes mellitus, smoking, or a family history of cardiovascular disease in a 1st degree relative.
- Patients who have stopped or changed the dosage of the preventive treatment of migraine in the last 2 weeks prior the screening visit (V0), including the use of calcium channel blockers, tricyclic antidepressants, beta blockers or serotonergic medications for any other indications;
- Use of prohibited medicine as shown in 9.3 item of this protocol;
- Inability to understand and report the categorical scale debilitating functional of study or symptoms diary;
- Has abused, in the opinion of the Investigator, any of the following drugs, currently or within the past 2 years: opioids, alcohol, barbiturates, benzodiazepine, cocaine or abuse of drugs for migraine treatment including narcotics ergotamines headache in the past 03 months;
- Hypersensitivity, intolerance, or contraindication to the use of naratriptan or naproxen, any of its components;
- Hypersensitivity, intolerance, or contraindication to the use of sulfonamides;
- History of malignancy ≤ 5 years or > 5 years without documentation of remission / cure, for example, melanoma, leukemia, lymphoma, myeloproliferative disorders and renal cell carcinoma of any duration. Exception: Subjects with basal cell skin cancers, squamous cell, and cervical cancer in situ may be eligible;
- Participation in last one year of clinical protocols, unless it can be direct benefit to patient;
- Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fixed-dose combination of naratriptan+naproxen
|
Tablets containing naratriptan 2,5 mg + naproxen 500 mg
|
ACTIVE_COMPARATOR: Naratriptan
|
Tablets containing naratriptan 2,5 mg
|
ACTIVE_COMPARATOR: Naproxen
|
Tablets containing naproxen 500 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Headache relief 2 hours after dosing, without use of rescue medication.
Time Frame: 2 hours after single dose of double-blind treatment
|
Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.
|
2 hours after single dose of double-blind treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
Time Frame: Collection of safety data throughout the whole study period
|
Collection of safety data throughout the whole study period
|
Headache relief 4 hours after dosing, without use of rescue medication
Time Frame: 4 hours after single dose of double-blind treatment
|
4 hours after single dose of double-blind treatment
|
Sustained headache relief over 24 hours, without use of rescue medication
Time Frame: 24 hours after single dose of double-blind treatment
|
24 hours after single dose of double-blind treatment
|
Pain-free response 2 and 4 hours after dosing, without use of rescue medication
Time Frame: 2 and 4 hours after single dose of double-blind treatment
|
2 and 4 hours after single dose of double-blind treatment
|
Sustained pain-free response over 24 hours, without use of rescue medication
Time Frame: 24 hours after single dose of double-blind treatment
|
24 hours after single dose of double-blind treatment
|
Freedom from photophobia, phonophobia and nausea 2 and 4 hours after dosing, without use of rescue medication
Time Frame: 2 and 4 hours after single dose of double-blind treatment
|
2 and 4 hours after single dose of double-blind treatment
|
Sustained freedom from photophobia, phonophobia and nausea from 2 through 24 hours after dosing, without use of rescue medication
Time Frame: 2 through 24 hours after single dose of double-blind treatment
|
2 through 24 hours after single dose of double-blind treatment
|
Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once
Time Frame: 2 and 24 hours after single dose of double-blind treatment
|
2 and 24 hours after single dose of double-blind treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Deusvenir S Carvalho, Federal University of São Paulo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2011
Primary Completion (ACTUAL)
March 1, 2012
Study Completion (ACTUAL)
March 1, 2012
Study Registration Dates
First Submitted
July 7, 2011
First Submitted That Met QC Criteria
July 8, 2011
First Posted (ESTIMATE)
July 11, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
October 19, 2016
Last Update Submitted That Met QC Criteria
October 18, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Serotonin Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Gout Suppressants
- Vasoconstrictor Agents
- Naproxen
- Naratriptan
Other Study ID Numbers
- ACH-NRP-03(05/11)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Fixed-dose combination of naratriptan+naproxen
-
University of Western Ontario, CanadaPfizerCompleted
-
International Union Against Tuberculosis and Lung...United States Agency for International Development (USAID)UnknownTuberculosisAlgeria, Bolivia, Colombia, Guinea, Mozambique, Nepal, Peru, Tanzania, Vietnam
-
Ache Laboratorios Farmaceuticos S.A.Withdrawn
-
University Hospital, GhentCompleted
-
Rockefeller UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
University Hospital, Clermont-FerrandMerck Sharp & Dohme LLCCompleted
-
Janssen-Cilag S.p.A.CompletedHuman Immunodeficiency Virus (HIV)Italy
-
Macfarlane Burnet Institute for Medical Research...St Vincent's Hospital MelbourneUnknownHepatitis C | Drug Abuse, IntravenousAustralia
-
Johnson & Johnson Consumer Inc. (J&JCI)Recruiting